LUPIN TRADED UP BY 19.20 POINTS OR 1.86% AT Rs.1,051.05

Lupin Pharma has partnered with Endoceutics, a women’s health focused Biotech Company, to commercialise Intrarosa in Canada.

Intrarosa is Endoceutic's flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.

Lupin has announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

The stock was trading at Rs.1, 051.05,up by 19.20 or 1.86%.It touched intraday high of Rs.1,052.80 and low of Rs.1,035.10.Market cap of the stock was at Rs.4768094.77 lakh.